ARCA biopharma - ABIO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.12
▲ +0.06 (2.91%)

This chart shows the closing price for ABIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ARCA biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABIO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ARCA biopharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.12.

This chart shows the closing price for ABIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in ARCA biopharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2019Ascendiant Capital MarketsSet TargetBuy$17.00Medium
2/27/2018Ascendiant Capital MarketsInitiated CoverageBuy ➝ Buy$2.00High
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
3/10/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
4/9/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/6/2022

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ARCA biopharma logo
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Read More

Today's Range

Now: $2.12
Low: $2.12
High: $2.12

50 Day Range

MA: $2.30
Low: $2.06
High: $2.47

52 Week Range

Now: $2.12
Low: $1.71
High: $2.95

Volume

100 shs

Average Volume

41,461 shs

Market Capitalization

$30.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Frequently Asked Questions

What sell-side analysts currently cover shares of ARCA biopharma?

The following equities research analysts have issued stock ratings on ARCA biopharma in the last year: StockNews.com.
View the latest analyst ratings for ABIO.

What is the current price target for ARCA biopharma?

0 Wall Street analysts have set twelve-month price targets for ARCA biopharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ARCA biopharma in the next year.
View the latest price targets for ABIO.

What is the current consensus analyst rating for ARCA biopharma?

ARCA biopharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ABIO.

What other companies compete with ARCA biopharma?

How do I contact ARCA biopharma's investor relations team?

ARCA biopharma's physical mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company's listed phone number is (720) 940-2200 and its investor relations email address is [email protected] The official website for ARCA biopharma is arcabio.com. Learn More about contacing ARCA biopharma investor relations.